Skip to main content
. Author manuscript; available in PMC: 2012 Apr 12.
Published in final edited form as: Vaccine. 2011 Mar 1;29(17):3183–3191. doi: 10.1016/j.vaccine.2011.02.040

Table 2c.

Antibody Responses to the Monovalent 2009 Influenza A (H1N1) Vaccine among Participants ≥35 Years Old

Antibody Level Total Cohort HIV+ HIV- Unadjusted p-value1 Adjusted OR2 (95% CI) Adjusted p-value2

Baseline/Day 0
 GMT ≤1:10 43/65 (66%) 23/32 (72%) 20/33 (61%) 0.434
 GMT >1:10 22/65 (34%) 9/32 (28%) 13/33 (39%)

Participants with Baseline Titer1:10 (Seroconversion)
 Day 28: Titer ≥1:40 24/43 (56%) 9/23 (39%) 15/20 (75%) 0.031 0.10 (0.01, 0.89) 0.055

 Month 6: Titer ≥1:40 17/43 (40%) 5/23 (22%) 12/20 (60%) 0.014 0.07 (0.01, 0.65) 0.029

All Participants Regardless of Baseline Titer (Seroprotection)
 Day 28: Titer ≥1:40 44/65 (68%) 18/32 (56%) 26/33 (79%) 0.066 0.24 (0.05, 1.07) 0.072

 Month 6: Titer ≥1:40 36/65 (55%) 12/32 (38%) 24/33 (73%) 0.006 0.16 (0.03, 0.62) 0.013

All Participants with a Day 28 Titer ≥1:40
 Month 6: Titer ≥1:40 35/44 (80%) 12/18 (67%) 23/26 (88%) 0.128 0.36 (0.05, 2.25) 0.287
1

Unadjusted p-value from Fisher’s exact test or T-test comparing HIV-infected with HIV-uninfected subjects.

2

Adjusted p-value from logistic regression comparing HIV-infected with HIV-uninfected subjects. Adjusted for age, race, number of seasonal influenza vaccinations in past three years, and number of household members.

CI, confidence interval; N, number; OR, odds ratio.